TSS
MRNA icon

Two Sigma Securities’s Moderna MRNA Stock Holding History

Two Sigma Securities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-124,300
Closed -$8.31M – 2630
2024
Q3 		$8.31M Buy
124,300
+38,400
+45% +$3.53M 0.14% 185
2024
Q2 		$10.2M Buy
85,900
+22,400
+35% +$2.83M 0.12% 206
2024
Q1 		$6.77M Sell
63,500
-26,600
-30% -$2.68M 0.07% 319
2023
Q4 		$8.96M Buy
90,100
+39,400
+78% +$3.31M 0.09% 225
2023
Q3 		$5.24M Sell
50,700
-87,800
-63% -$9.79M 0.06% 353
2023
Q2 		$16.8M Buy
138,500
+117,200
+550% +$15.6M 0.25% 81
2023
Q1 		$3.27M Sell
21,300
-2,000
-9% -$330K 0.07% 366
2022
Q4 		$4.19M Sell
23,300
-59,200
-72% -$9.68M 0.13% 191
2022
Q3 		$9.76M Sell
82,500
-32,700
-28% -$4.96M 0.3% 61
2022
Q2 		$16.5M Buy
115,200
+92,000
+397% +$13.2M 0.58% 22
2022
Q1 		$4M Buy
23,200
+20,600
+792% +$3.47M 0.14% 169
2021
Q4 		$660K Sell
2,600
-15,700
-86% -$4.59M 0.03% 405
2021
Q3 		$7.04M Buy
18,300
+9,700
+113% +$3.58M 0.21% 74
2021
Q2 		$2.02M Buy
+8,600
New +$1.54M 0.06% 235
2021
Q1 		– Sell
-5,100
Closed -$533K – 1424
2020
Q4 		$533K Buy
+5,100
New +$516K 0.01% 658

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Two Sigma Securities's MRNA Position: Q4 2023 in Review

Two Sigma Securities sold out of Moderna (MRNA) in Q4 2023, closing a stake of 8,326 shares — an estimated $700K sold.

Two Sigma Securities first reported a position in MRNA in Q4 2020 and held it in 12 quarters. The position peaked at $7.74M in Q1 2023. 884 funds tracked by Wall St. Rank hold MRNA as of Q4 2023.

  • Two Sigma Securities reported no remaining Moderna position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Securities sold 8,326 Moderna shares in Q4 2023, an estimated $700K.
  • Two Sigma Securities first reported a position in Moderna in Q4 2020 and held it in 12 quarters.
  • Two Sigma Securities's Moderna position peaked at $7.74M in Q1 2023.
  • 884 funds tracked by Wall St. Rank held Moderna as of Q4 2023.

Based on Two Sigma Securities's 13F filing for Q4 2023, filed 14 Feb 2024.